TRIAMTERENE (triamterene) by Biocon is clinical pharmacology triamterene has a unique mode of action; it inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone). Approved for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, the nephrotic syndrome and 5 more indications. First approved in 2022.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Triamterene has a unique mode of action; it inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone). This activity is not directly related…
Potassium-sparing Diuretic
Worked on TRIAMTERENE at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.